NCT06476470 Taiwan Interstitial Lung Disease Multi-center Investigation and Registry
| NCT ID | NCT06476470 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Taichung Veterans General Hospital |
| Condition | Interstitial Lung Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2024-03-10 |
| Primary Completion | 2033-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2024-03-10 with a primary completion date of 2033-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Taiwan Interstitial Lung Disease (ILD) Multi-center Investigation and Registry aims to evaluate the long-term outcomes of patients with fibrotic interstitial lung disease. This prospective observational registry will collect comprehensive clinical data from multiple centers, including epidemiological information, comorbidities, questionnaire results, routine blood tests, biochemical tests, pulmonary function tests, echocardiograms, and cardiopulmonary exercise tests (CPET), all following a standardized protocol. Key components of the registry include annual HRCT scans, annual CPETs, biobank blood samples, and biannual echocardiograms and pulmonary function tests. The main questions the registry aims to answer are: 1. Differences in all-cause mortality among ILD patients of different etiologies. 2. Differences in the annual risk of acute exacerbation among ILD patients of different etiologies. 3. Effectiveness of current anti-fibrotic drugs in treating IPF and ILD of different etiologies. 4. Predictive ability of HRCT imaging features for mortality risk in ILD patients. 5. Impact of comorbidities on the mortality risk of ILD patients. 6. Predictive ability of biomarkers for disease progression and mortality.
Eligibility Criteria
Inclusion Criteria: 1. Aged over 18 years old. 2. Diagnosed as ILD by a pulmonologist, rheumatologist or radiologist 3. Various casue of ILD, including Idiopathic pulmonary fibrosis (IPF), Connective tissue disease-associated interstitial lung disease (CTD-ILD), Unclassifed ILD, drug-induced ILD, lymphangioleiomyomatosis (LAM), and sarcoidosis-associated ILD. Exclusion Criteria: 1. Under 18 years of age. 2. Failure to express informed consent in person.
Contact & Investigator
Pin-Kuei Fu, MD., Ph.D
PRINCIPAL INVESTIGATOR
Taichung Veterans General Hospital
Frequently Asked Questions
Who can join the NCT06476470 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Interstitial Lung Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06476470 currently recruiting?
Yes, NCT06476470 is actively recruiting participants. Contact the research team at yetquen@gmail.com for enrollment information.
Where is the NCT06476470 trial being conducted?
This trial is being conducted at Taichung, Taiwan.
Who is sponsoring the NCT06476470 clinical trial?
NCT06476470 is sponsored by Taichung Veterans General Hospital. The principal investigator is Pin-Kuei Fu, MD., Ph.D at Taichung Veterans General Hospital. The trial plans to enroll 10,000 participants.